Olamkicept is under clinical development by Ferring International Center and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Olamkicept’s likelihood of approval (LoA) and phase transition for Ulcerative Colitis took place on 22 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Olamkicept Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Olamkicept overview

olamkicept (TJ-301) is under development for the treatment of inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis. The drug candidate is administered through intravenous route. The drug candidate is a recombinant soluble gp130 (sgp130) protein. It was also under development for rheumatoid arthritis (RA). It was also under development for the treatment of neuromyelitis optica, systemic sclerosis, castleman’s disease and system vasculitis

Ferring International Center overview

Ferring International Center (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility; FE 202767 for Lactation; RBX2660 enema for difficile infection among others. It has production facilities in Europe, Asia, and a manufacturing site in the US. Ferring is headquartered in Saint-Prex, Switzerland.

Quick View Olamkicept LOA Data

Report Segments
  • Innovator
Drug Name
  • Olamkicept
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Gastrointestinal
  • Immunology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.